Truncal somatic cancer driver mutations across this study cohort include AKT1, ATM, BCOR, CHD4, KRAS, MAP3K1, and PIK3CA; conversely, branch somatic cancer driver mutations include ERBB2, FOXA1, and PPM1D. In our cohort, EGFR mutations were confined to lung cancers, with three out of four (75%) NSCLC patients found to harbor a truncal variant in at least one reportable mutation in EGFR [13]. This evidence concerns the gene MAP3K1 and lung carcinoma.